Association of Serum Adiponectin with Coronary Artery Disease and Multi-Vessel Involvement: A Case-Control Study
DOI:
https://doi.org/10.56286/7vh09h45Keywords:
Adiponectin, Coronary Artery Disease, Biomarkers, Coronary Angiography, Atherosclerosis, ROC CurveAbstract
Background: Adiponectin is an adipocyte-derived protein with anti-atherogenic, anti-inflammatory, and insulin-sensitising properties, and hypoadiponectinaemia has been linked to coronary artery disease (CAD). This study evaluated the association of serum adiponectin with angiographically confirmed CAD compared with healthy individuals, and explored its relationship with the anatomical extent of disease. Methods: In this case-control study conducted between January and May 2026, serum adiponectin was measured by enzyme-linked immunosorbent assay in 60 adults with CAD confirmed by coronary angiography (≥50% luminal stenosis in at least one major coronary artery) and 40 healthy controls. Patients were stratified by the number of diseased vessels (single, double, triple). Group differences were assessed using the Welch t-test and Mann–Whitney U test; the extent relationship was examined by one-way analysis of variance (ANOVA), the Kruskal–Wallis test, and Spearman correlation. Multivariable logistic regression, using Firth's penalized method to accommodate near-complete separation between groups, tested whether adiponectin was independently associated with CAD after adjustment for age, diabetes, body mass index, hypertension, lipid parameters, smoking, and sex. Discrimination was assessed by receiver-operating-characteristic (ROC) analysis. Results: Serum adiponectin was markedly lower in CAD patients than in controls (6.85 ± 2.39 vs 14.45 ± 3.72 ng/mL; p < 0.001). The biomarker showed high discriminatory performance for CAD in this cohort (area under the curve [AUC] 0.955, 95% CI 0.91–0.99); a cut-off of 9.59 ng/mL yielded 90.0% sensitivity and 92.5% specificity, with a positive predictive value of 94.7% and a negative predictive value of 86.0%. Adiponectin remained independently associated with CAD after multivariable adjustment (adjusted odds ratio [OR] 0.51 per 1 ng/mL, 95% CI 0.34–0.74, p = 0.0005) and after direct adjustment for fasting glucose (adjusted OR 0.50, 95% CI 0.33–0.75, p = 0.0009), and adding adiponectin to a clinical-risk-factor-only model increased discrimination from AUC 0.940 to 0.992 (ΔAUC = 0.052, p < 0.0001). Adiponectin decreased progressively across single-, double-, and triple-vessel disease (7.64 ± 2.86, 6.79 ± 2.22, 6.24 ± 1.99 ng/mL), but this trend did not reach statistical significance (ANOVA p = 0.185; Spearman ρ = –0.24, p = 0.070); post-hoc power for this comparison was low (≈ 0.37). Adiponectin correlated inversely with fasting glucose (r = –0.41, p < 0.001) and age (r = –0.24, p = 0.017). Conclusions: Serum adiponectin showed strong discriminatory ability for CAD presence in this cohort, independent of the clinical covariates included in the multivariable model. A weak inverse association with multi-vessel involvement did not reach statistical significance and warrants evaluation in larger, adequately powered cohorts.
Downloads
References
Charach L, Rabinovich A, Ophir O, et al. Using the Gensini score to estimate severity of STEMI, NSTEMI, unstable angina, and anginal syndrome. Medicine. 2021;100(41):e27331. doi: https://doi.org/10.1097/MD.0000000000027331
Achari AE, Jain SK. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci. 2017;18(6):1321. doi: https://doi.org/10.3390/ijms18061321
Kobashi C, Urakaze M, Kishida M, et al. Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res. 2005;97(12):1245–1252. doi: https://doi.org/10.1161/01.RES.0000194328.57164.36
Antoniades C, Antonopoulos AS, Tousoulis D, Stefanadis C. Adiponectin: from obesity to cardiovascular disease. Obes Rev. 2009;10(3):269–279. doi: https://doi.org/10.1111/j.1467-789X.2009.00571.x
Nakamura Y, Shimada K, Fukuda D, et al. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart. 2004;90(5):528–533. doi: https://doi.org/10.1136/hrt.2003.011114
Otsuka F, Sugiyama S, Kojima S, et al. Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease. J Am Coll Cardiol. 2006;48(6):1155–1162. doi: https://doi.org/10.1016/j.jacc.2006.05.054
von Eynatten M, Schneider JG, Humpert PM, et al. High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men. Atherosclerosis. 2008;199(1):123–128. doi: https://doi.org/10.1016/j.atherosclerosis.2007.10.002
Rahmani A, Toloueitabar Y, Mohsenzadeh Y, et al. Association between plasma leptin/adiponectin ratio and insulin resistance indexes and coronary artery disease. BMC Cardiovasc Disord. 2020;20(1):397. doi: https://doi.org/10.1186/s12872-020-01723-7
Zhao S, Kusminski CM, Scherer PE. Adiponectin, leptin and cardiovascular disorders. Circ Res. 2021;128(1):136–149. doi: https://doi.org/10.1161/CIRCRESAHA.120.314458
Choi HM, Doss HM, Kim KS. Multifaceted physiological roles of adiponectin in inflammation and diseases. Int J Mol Sci. 2020;21(4):1219. doi: https://doi.org/10.3390/ijms21041219
Fisman EZ, Tenenbaum A. Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovasc Diabetol. 2014;13:103. doi: https://doi.org/10.1186/1475-2840-13-103
Yanai H, Yoshida H. Beneficial effects of adiponectin on glucose and lipid metabolism and atherosclerotic progression: mechanisms and perspectives. Int J Mol Sci. 2019;20(5):1190. doi: https://doi.org/10.3390/ijms20051190
Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab. 2001;86(8):3815–3819. doi: https://doi.org/10.1210/jcem.86.8.7741
Maeda N, Takahashi M, Funahashi T, et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50(9):2094–2099. doi: https://doi.org/10.2337/diabetes.50.9.2094
Han W, Yang S, Xiao H, et al. Role of adiponectin in cardiovascular diseases related to glucose and lipid metabolism disorders. Int J Mol Sci. 2022;23(24):15627. doi: https://doi.org/10.3390/ijms232415627
Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23(1):85–89. doi: https://doi.org/10.1161/01.ATV.0000048856.22331.50
Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291(14):1730–1737. doi: https://doi.org/10.1001/jama.291.14.1730
Mohamadshahi M, Haidari F, Mohammadi-Asl J, et al. Association of dietary patterns with leptin/adiponectin ratio and severity of coronary artery disease. J Diabetes Metab Disord. 2021;20(1):219–227. doi: https://doi.org/10.1007/s40200-021-00801-7
Sawada T, Shite J, Shinke T, et al. Low plasma adiponectin levels are associated with presence of thin-cap fibroatheroma in men with stable coronary artery disease. Int J Cardiol. 2010;142(3):250–256. doi: https://doi.org/10.1016/j.ijcard.2008.12.201
Li Q, Wang L, Tan W, et al. Plasma adiponectin levels in relation to prognosis in patients with angiographic coronary artery disease. Metabolism. 2012;61(12):1745–1752. doi: https://doi.org/10.1016/j.metabol.2012.05.018
Kim JY, Ahn SV, Yoon JH, et al. Usefulness of metabolic syndrome score in the prediction of angiographic coronary artery disease severity according to the presence of diabetes mellitus. Cardiovasc Diabetol. 2013;12:108. doi: https://doi.org/10.1186/1475-2840-12-108
Shibata R, Sato K, Pimentel DR, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med. 2005;11(10):1096–1103. doi: https://doi.org/10.1038/nm1295
Gruzdeva O, Borodkina D, Belik E, et al. Expression of adipocytokines in heart fat depots depending on the degree of coronary artery atherosclerosis in patients with coronary artery disease. PLoS One. 2021;16(3):e0248716. doi: https://doi.org/10.1371/journal.pone.0248716
Hong ES, Lim C, Choi HY, et al. The amount of C1q–adiponectin complex is higher in the serum and the complex localizes to perivascular areas of fat tissues and the intimal–medial layer of blood vessels of coronary artery disease patients. Cardiovasc Diabetol. 2015;14:50. doi: https://doi.org/10.1186/s12933-015-0212-5
Jung HN, Jung CH. The role of anti-inflammatory adipokines in cardiometabolic disorders: moving beyond adiponectin. Int J Mol Sci. 2021;22(24):13529. doi: https://doi.org/10.3390/ijms222413529
Downloads
Published
License
Copyright (c) 2026 Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
How to Cite
